The company’s total revenues in 2017 stood at some 35 billion euros. This amount was generated by four segments: Pharmaceuticals, Consumer Health, Animal Health, and Crop Science. The material science segment under the name Covestro was spun-off during 2015. Thus, the health-related segments now make up almost 70 percent of Bayer’s total revenue. Bayer’s best-selling pharmaceutical products are anticoagulant Xarelto and fusion protein Eylea, generating 3.3 billion and 1.9 billion U.S. dollars, respectively.
Since 2016, Bayer has had increased media attention due to the announced acquisition of U.S. agrochemical company Monsanto. The merger of these two companies would create the leading seeds and agrochemical company, with a monopolistic position worldwide. Because of the antitrust proceedings, the merger is still pending. However, it looks like Bayer will receive a ‘green light’ from all relevant authorities by early-2018. Monsanto has struggled with a negative reputation, largely based on the production of controversial herbicides and genetically manipulated seeds. In line with this, the whole mega-merger of Bayer and Monsanto is widely criticized.